Early postmenopausal bone loss in hyperthyroidism

被引:26
作者
Ben-Shlomo, A
Hagag, P
Evans, S
Weiss, M [1 ]
机构
[1] Assaf Harofeh Med Ctr, Endocrine Inst, IL-70300 Zerifin, Israel
[2] Tel Aviv Univ, Sakler Fac Med, IL-69978 Tel Aviv, Israel
[3] Assaf Harofeh Med Ctr, Dept Biochem, IL-70300 Zerifin, Israel
关键词
D O I
10.1016/S0378-5122(00)00179-1
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: To evaluate the effect of hyperthyroidism on bone in relation to the menopausal state. Methods: Fifty-nine hyperthyroid HYPER), 40 hypothyroid (HYPO), and 51 control euthyroid (EUTH) women were studied. Bone mineral density (BMD) was assessed by dual X-rays absorptiometry (DXA) at the lumbar spine, and at the femoral neck. A multi-site QUS device evaluated speed of sound (SOS) at the radius (RAD), tibia (TIB), metatarsus (MTR), and phalanx (PLX). Bone markers used were serum bone specific alkaline phosphatase (BSAP) and urinary deoxypyridinoline (DPD). Results: At all sites, SOS was lower in HYPER than in EUTH (RAD P < 0.05, TIB P < 0.01, MTR P < 0.05, PLX P = 0.01). The low SOS was only noted at the early postmenopausal period. BMD at the femoral neck but not at the lumbar spine was lower in HYPER as compared to EUTH (P < 0.05). Both femoral neck and tibia were the sites with the highest odds ratio for being hyperthyroid (2.3 and 2.04, respectively), There was no correlation between BMD or SOS and FT4, TT3 or duration of hyperthyroidism. BSAP and DPD positively correlated with FT4 and TT3 (P < 0.05), Conclusions: This study suggests that hyperthyroidism affects bone mineralization especially during the early postmenopausal period, and the effect is mainly at the cortical bone. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 40 条
  • [1] ACOTTO CG, 1995, J BONE MINER RES, V10, pS400
  • [2] ALDIN EV, 1991, AM J MED, V90, P360
  • [3] Low thyrotropin levels are not associated with bone loss in older women: A prospective study
    Bauer, DC
    Nevitt, MC
    Ettinger, B
    Stone, K
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (09) : 2931 - 2936
  • [4] Molecular basis and clinical application of biological markers of bone turnover
    Calvo, MS
    Eyre, DR
    Gundberg, CM
    [J]. ENDOCRINE REVIEWS, 1996, 17 (04) : 333 - 368
  • [5] A THERAPEUTIC DILEMMA - SUPPRESSIVE DOSES OF THYROXINE SIGNIFICANTLY REDUCE BONE-MINERAL MEASUREMENTS IN BOTH PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN WITH THYROID-CARCINOMA
    DIAMOND, T
    NERY, L
    HALES, I
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (06) : 1184 - 1188
  • [6] KINETICS OF TRABECULAR BONE-RESORPTION AND FORMATION IN HYPOTHYROIDISM - EVIDENCE FOR A POSITIVE BALANCE PER REMODELING CYCLE
    ERIKSEN, EF
    MOSEKILDE, L
    MELSEN, F
    [J]. BONE, 1986, 7 (02) : 101 - 108
  • [7] CHANGES IN BONE MASS DURING PROLONGED SUBCLINICAL HYPERTHYROIDISM DUE TO L-THYROXINE TREATMENT - A METAANALYSIS
    FABER, J
    GALLOE, AM
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1994, 130 (04) : 350 - 356
  • [8] BONE-MINERAL DENSITY IN PATIENTS WITH ENDOGENOUS SUBCLINICAL HYPERTHYROIDISM - IS THIS THYROID STATUS A RISK FACTOR FOR OSTEOPOROSIS
    FOLDES, J
    TARJAN, G
    SZATHMARI, M
    VARGA, F
    KRASZNAI, I
    HORVATH, C
    [J]. CLINICAL ENDOCRINOLOGY, 1993, 39 (05) : 521 - 527
  • [9] LONG-TERM THYROXINE TREATMENT AND BONE-MINERAL DENSITY
    FRANKLYN, JA
    BETTERIDGE, J
    DAYKIN, J
    HOLDER, R
    OATES, GD
    PARLE, JV
    LILLEY, J
    HEATH, DA
    SHEPPARD, MC
    [J]. LANCET, 1992, 340 (8810) : 9 - 13
  • [10] FRASER SA, 1971, LANCET, V1, P981